Migraine drug Vyepti was launched in the US in April 2020, and thanks to the Covid-19 crisis, this did not go well. CEO at Lundbeck Deborah Dunsire thinks the drug has the potential to become a blockbuster, but that requires a boost to the marketing of the drug, Danish financial daily Børsen reports.
"With the growth in the migraine market and the market for cluster headaches, which often follow, and the potential for other indications, Vyepti will be a blockbuster drug in the mid-2030s, right before the patent expires. I am 100 percent sure of that," Dunsire says.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.